Finn Patrick John 4
4 · Twist Bioscience Corp · Filed Feb 17, 2026
Research Summary
AI-generated summary of this filing
Twist Bioscience (TWST) President Finn P. John Exercises Options, Sells Shares
What Happened
Finn Patrick John, President and COO of Twist Bioscience (TWST), exercised stock options on Feb 12–13, 2026 to acquire 3,712 shares (strikes $23.33 and $26.66; total cash paid ~$93,967). He also sold 5,250 shares in open-market transactions (3,500 shares on 2/12 at $50.23; 1,750 shares on 2/13 at $50.04) for aggregate proceeds of about $263,360. The Form 4 also records 3,712 shares disposed at $0 in connection with the option exercises (see Key Details).
Key Details
- Transaction dates: Feb 12–13, 2026.
- Option exercises (acquired): 1,000 @ $23.33 ($23,330); 1,500 @ $26.66 ($39,990); 500 @ $23.33 ($11,665); 712 @ $26.66 ($18,982). Total cash paid ≈ $93,967.
- Open-market sales (disposed): 3,500 @ $50.23 ($175,788) on 2/12; 1,750 @ $50.04 ($87,572) on 2/13. Total proceeds ≈ $263,360. Price range reported $50.00–$50.51; F2 notes a weighted average and range.
- Exercise-related disposals: 3,712 shares listed as disposed at $0 (derivative). These match the number of shares exercised and likely reflect surrender/netting or tax withholding related to the exercises (common reporting treatment).
- Shares owned after the transactions: not specified in the provided excerpt of the filing.
- Footnotes of note: F1 — trades were conducted under a previously adopted Rule 10b5-1 trading plan (May 13, 2025). F3/F4 — the options were immediately exercisable with standard vesting schedules described in the filing.
- Filing timeliness: Form filed Feb 17, 2026 for trades on Feb 12–13; this appears to be after the typical 2-business-day Form 4 deadline (i.e., the filing may be late).
Context
This was an option exercise combined with same-period open-market sales. The matching number of exercised shares and $0 disposals suggests some or all exercised shares were surrendered or netted (or used for tax/settlement), while additional stock was sold from holdings in open market trades. Exercises are not direct bullish purchases unless shares are retained; open-market sales are typically routine or plan-driven—here the trades were executed under a 10b5-1 plan (F1), which formalizes scheduled trades and reduces implication of opportunistic timing.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-12$23.33/sh+1,000$23,330→ 308,788 total - Exercise/Conversion
Common Stock
[F1]2026-02-12$26.66/sh+1,500$39,990→ 310,288 total - Sale
Common Stock
[F2]2026-02-12$50.23/sh−3,500$175,788→ 306,788 total - Exercise/Conversion
Common Stock
[F1]2026-02-13$23.33/sh+500$11,665→ 307,288 total - Exercise/Conversion
Common Stock
[F1]2026-02-13$26.66/sh+712$18,982→ 308,000 total - Sale
Common Stock
[F2]2026-02-13$50.04/sh−1,750$87,572→ 306,250 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2026-02-12−1,500→ 33,012 totalExercise: $26.66Exp: 2028-11-18→ Common Stock (1,500 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2026-02-12−1,000→ 18,705 totalExercise: $23.33Exp: 2029-10-23→ Common Stock (1,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2026-02-13−712→ 32,300 totalExercise: $26.66Exp: 2028-11-18→ Common Stock (712 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F1][F4]2026-02-13−500→ 18,052 totalExercise: $23.33Exp: 2029-10-23→ Common Stock (500 underlying)
Footnotes (4)
- [F1]The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025.
- [F2]Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.51 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- [F4]The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date.